Dublin, Jan. 13, 2026 (GLOBE NEWSWIRE) -- The "Paliperidone (CAS 144598-75-4) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ...
If approved, paliperidone palmitate 3-monthly injection will be the first once-every-three-months treatment for schizophrenia in the UK Janssen UK announced today that the Committee for Medicinal ...
Please provide your email address to receive an email when new articles are posted on . Long-acting injectable paliperidone use was associated with significant improvement in clinical and functional ...
The FDA approved a new monthly paliperidone palmitate (Erzofri) extended-release injectable suspension for treating schizophrenia in adults, Luye Pharma announced. An atypical antipsychotic, ...
This analysis used propensity score matching of subjects from randomized placebo-controlled schizophrenia studies to compare paliperidone ER 6–12 mg/day with risperidone 2–4 mg/day and risperidone 4–6 ...
Results served as basis for regulatory filing with U.S. Food and Drug Administration and designation as Priority Review TITUSVILLE, N.J., March 29, 2015 /PRNewswire/ -- Three-month paliperidone ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Long-acting injectable formulations of paliperidone, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results